Literatuur
- Grothey A et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018. 378(13): 1177-88
- Simkens LH et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015. 385(9980): 1843-52
- Goey KKH et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol. 2017. 28(9): 2128-34
- Hegewisch-Becker S. et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015. 16(13): 1355-69
- Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008. 371(9617): 1007-16
- Loupakis F. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014; 371(17): 1609-18
- Gruenberger T et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015. 26(4): 702-8
- Xu RH et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. The Lancet Oncology. 2018 19(5): 660-71
- Schmiegel W. et al. Capecitabine / irinotecan or capecitabine / oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol. 2013. 24(6): 1580-7
- Yan TD et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27(36): 6237-42
- Sugarbaker PH. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia. Ann Surg Oncol. 2010. 17(6): 1710-2; author reply 3-4
- Bahadoer RR et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2021. 22(1): 29-42
- Dijkstra EA et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023 Oct 1; 278(4): 766-772
- Prager GW et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023. 388: 1657-67
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over Colorectaal carcinoom.
Richtlijnen
Ga naar de richtlijn Colorectaal carcinoom in de FMS richtlijnendatabase.
Ga naar de richtlijn Colorectaal carcinoom van VKGN - StOET.
Ga naar de richtlijn Poliepen (gastro-intestinaal) van VKGN - StOET.